{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:30:51Z","timestamp":1793129451264,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bneo.2025.100110","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T06:08:06Z","timestamp":1746943686000},"page":"100110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed\/refractory acute myeloid leukemia"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-1741","authenticated-orcid":false,"given":"Martin","family":"Hutchings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koorosh","family":"Korfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9492","authenticated-orcid":false,"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Martinez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Vives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7099-8054","authenticated-orcid":false,"given":"Tsai-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Frigeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Garciaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Salamero Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Peng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-9952","authenticated-orcid":false,"given":"Karen","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bajel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9302-3786","authenticated-orcid":false,"given":"Anne Catherine","family":"Bretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2159-2880","authenticated-orcid":false,"given":"Jan","family":"Attig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Nassiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Rutishauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-7280","authenticated-orcid":false,"given":"Christian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. May","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-8596","authenticated-orcid":false,"given":"Gabriel","family":"Schnetzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Vauleon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-7730","authenticated-orcid":false,"given":"Muriel","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Hinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Keshelava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-9469","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bneo.2025.100110_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2025.100110_bib2","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.3390\/curroncol29090491","article-title":"Management of acute myeloid leukemia: a review for general practitioners in oncology","volume":"29","author":"Stubbins","year":"2022","journal-title":"Curr Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100110_bib4","first-page":"632","article-title":"Emerging treatments in acute myeloid leukemia: current standards and unmet challenges","volume":"15","author":"Percival","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"issue":"11","key":"10.1016\/j.bneo.2025.100110_bib5","doi-asserted-by":"crossref","first-page":"9667","DOI":"10.3390\/ijms24119667","article-title":"A direct comparison, and prioritisation, of the immunotherapeutic targets expressed by adult and paediatric acute myeloid leukaemia cells: a systematic review and meta-analysis","volume":"24","author":"Morris","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"25","key":"10.1016\/j.bneo.2025.100110_bib6","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.2020010477","article-title":"Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody","volume":"138","author":"Augsberger","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2025.100110_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215699","article-title":"Therapeutic bispecific antibodies against intracellular tumor antigens","volume":"538","author":"Xu","year":"2022","journal-title":"Cancer Lett"},{"issue":"14","key":"10.1016\/j.bneo.2025.100110_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399407000336","article-title":"The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis","volume":"9","author":"Ariyaratana","year":"2007","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.bneo.2025.100110_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1340909","article-title":"Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia","volume":"14","author":"Ahmed","year":"2024","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100110_bib10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3324\/haematol.2009.011908","article-title":"Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia","volume":"95","author":"Gianfaldoni","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bneo.2025.100110_bib11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12185-024-03795-z","article-title":"WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia","volume":"120","author":"Arai","year":"2024","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100110_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002404","article-title":"Acute multiple organ failure in adult mice deleted for the developmental regulator Wt1","volume":"7","author":"Chau","year":"2011","journal-title":"PLoS Genet"},{"issue":"7","key":"10.1016\/j.bneo.2025.100110_bib13","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.bneo.2025.100110_bib14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100110_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1117","article-title":"Toll-like receptor 7\/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial","volume":"9","author":"Lichtenegger","year":"2020","journal-title":"Clin Transl Immunology"},{"issue":"4","key":"10.1016\/j.bneo.2025.100110_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bneo.2025.100110_bib17","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2025.100110_bib18","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00204-017-2002-1","article-title":"Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury","volume":"91","author":"Proctor","year":"2017","journal-title":"Arch Toxicol"},{"issue":"10396","key":"10.1016\/j.bneo.2025.100110_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bneo.2025.100110_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2181016","article-title":"Strategies for clinical dose optimization of T cell-engaging therapies in oncology","volume":"15","author":"Ball","year":"2023","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.bneo.2025.100110_bib21","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1214\/13-AOAS661","article-title":"Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity","volume":"7","author":"Liu","year":"2013","journal-title":"Ann Appl Stat"},{"key":"10.1016\/j.bneo.2025.100110_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106436","article-title":"Rolling continual reassessment method with overdose control: an efficient and safe dose escalation design","volume":"107","author":"Zhu","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"7","key":"10.1016\/j.bneo.2025.100110_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002582","article-title":"Src\/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies","volume":"9","author":"Leclercq","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.bneo.2025.100110_bib24","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Br\u00f6ske","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bneo.2025.100110_bib25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"suppl 15","key":"10.1016\/j.bneo.2025.100110_bib26","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","article-title":"Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"38","author":"Ravandi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.bneo.2025.100110_bib27","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","article-title":"Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia","volume":"7","author":"Ravandi","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100110_bib28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2019-127977","article-title":"Preliminary results from a Phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33\/CD3 BiTE\u00ae (Bispecific T-Cell Engager) in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML)","volume":"134","author":"Subklewe","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100110_bib29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8+ T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"31","key":"10.1016\/j.bneo.2025.100110_bib30","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100110_bib31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.bneo.2025.100110_bib32","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1172\/JCI81187","article-title":"TIGIT predominantly regulates the immune response via regulatory T cells","volume":"125","author":"Kurtulus","year":"2015","journal-title":"J Clin Invest"},{"issue":"631","key":"10.1016\/j.bneo.2025.100110_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg8070","article-title":"Targeting an alternate Wilms\u2019 tumor Antigen-1 peptide bypasses immunoproteasome dependency","volume":"14","author":"Lahman","year":"2022","journal-title":"Sci Trans Med"},{"issue":"12","key":"10.1016\/j.bneo.2025.100110_bib34","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/cncr.31370","article-title":"Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bneo.2025.100110_bib35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/life11060465","article-title":"BiTEs, DARTS, BiKEs and TriKEs - are antibody based therapies changing the future treatment of AML?","volume":"11","author":"Allen","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.bneo.2025.100110_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00213","article-title":"Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cells immunity","volume":"8","author":"Lamble","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100110_bib37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bneo.2025.100110_bib38","article-title":"Approaching hemophagocytic lymphohistiocytosis [published correction appears in Front Immunol. 2024:15:1369687]","volume":"14","author":"Chinnici","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100110_bib39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood.2023020715","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in Sweden: incidence, clinical characteristics, and survival","volume":"143","author":"L\u00f6fstedt","year":"2024","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bneo.2025.100110_bib40","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bneo.2025.100110_bib41","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2015-01-551622","article-title":"How I treat hemophagocytic lymphohistiocytosis in the adult patient","volume":"125","author":"Schram","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2025.100110_bib42","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00277-018-3254-4","article-title":"Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents\u2014a single centre experience of 20 years","volume":"97","author":"Strenger","year":"2018","journal-title":"Ann Haemat"},{"issue":"3","key":"10.1016\/j.bneo.2025.100110_bib43","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1751143719893865","article-title":"Haemophagocytic lymphohistiocytosis in adult critical care","volume":"21","author":"Bauchmuller","year":"2020","journal-title":"J Intensive Care Soc"},{"issue":"3","key":"10.1016\/j.bneo.2025.100110_bib44","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3324\/haematol.2013.097394","article-title":"Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy","volume":"99","author":"Delavigne","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bneo.2025.100110_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13742","article-title":"First- in- human study of JNJ- 67571244, a CD33 \u00d7 CD3 bispecific antibody, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"17","author":"Narayan","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.bneo.2025.100110_bib46","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in MajesTEC-1","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100110_bib47","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2023-179776","article-title":"Molecular mechanisms underlying response and resistance to glofitamab","volume":"142","author":"Nassiri","year":"2023","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bneo.2025.100110_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.bneo.2025.100110_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2022.03.003","article-title":"Epigenetic maintenance strategies after allogeneic stem cell transplantation in acute myeloid leukemia","volume":"109","author":"Yan","year":"2022","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100110_bib50","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41375-023-02127-0","article-title":"Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment","volume":"38","author":"H\u00e4nel","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2025.100110_bib51","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcyt.2021.10.007","article-title":"Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy","volume":"24","author":"Atilla","year":"2022","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.bneo.2025.100110_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","article-title":"Targeting CLL-1 for acute myeloid leukemia therapy","volume":"12","author":"Ma","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bneo.2025.100110_bib53","article-title":"Targeting PRAME for acute myeloid leukemia therapy","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.bneo.2025.100110_bib54","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1158\/0008-5472.CAN-13-0677","article-title":"MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells","volume":"73","author":"Stroopinsky","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bneo.2025.100110_bib55","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100110_bib56","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.1007\/s00432-023-04737-8","article-title":"Cancer immune escape: the role of antigen presentation machinery","volume":"149","author":"Kallingal","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100110_bib57","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3390\/biomedicines10081842","article-title":"Therapeutic strategies to enhance tumor antigenicity: making the tumor detectable by the immune system","volume":"10","author":"Meraviglia-Crivelli","year":"2022","journal-title":"Biomedicines"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:11:19Z","timestamp":1756127479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2950328025000457"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100110","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed\/refractory acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100110"}}